Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EKSO 
Ekso Bionics Holdings Inc (EKSO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: EKSO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.75
1 Year Target Price $6.75
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.15% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.04M USD | Price to earnings Ratio - | 1Y Target Price 6.75 |
Price to earnings Ratio - | 1Y Target Price 6.75 | ||
Volume (30-day avg) 2 | Beta 1.11 | 52 Weeks Range 2.73 - 17.32 | Updated Date 10/19/2025 |
52 Weeks Range 2.73 - 17.32 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -75.66% | Operating Margin (TTM) -193.24% |
Management Effectiveness
Return on Assets (TTM) -30.17% | Return on Equity (TTM) -96.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14043712 | Price to Sales(TTM) 0.82 |
Enterprise Value 14043712 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 0.96 | Enterprise Value to EBITDA 0.46 | Shares Outstanding 2611788 | Shares Floating 2244727 |
Shares Outstanding 2611788 | Shares Floating 2244727 | ||
Percent Insiders 4.95 | Percent Institutions 2.75 |
Upturn AI SWOT
Ekso Bionics Holdings Inc
Company Overview
History and Background
Ekso Bionics was founded in 2005. The company focuses on developing and manufacturing exoskeletons for medical and industrial use. Initially focused on military applications, it shifted to medical and industrial markets.
Core Business Areas
- Medical: Designs, develops, and markets exoskeletons for rehabilitation and mobility assistance for individuals with spinal cord injuries, stroke, and other neurological conditions.
- Industrial: Develops and sells exoskeletons for industrial applications, reducing strain and fatigue for workers in physically demanding jobs.
Leadership and Structure
Scott Davis is the CEO of Ekso Bionics. The company has a board of directors overseeing strategic direction. The organizational structure includes departments for engineering, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- EksoNR: An FDA-cleared exoskeleton used in rehabilitation centers to help patients with neurological conditions regain the ability to walk. Revenue is derived from sales and leases to rehab facilities. Competitors include ReWalk Robotics (RWLK) and Cyberdyne.
- EksoVest: An upper body exoskeleton for industrial workers, designed to reduce fatigue and support repetitive tasks. Revenue generated through direct sales and partnerships with industrial companies. Competitors include SuitX and Ottobock.
Market Dynamics
Industry Overview
The exoskeleton market is growing due to increasing demand for rehabilitation solutions and workplace safety improvements. Advancements in robotics, sensors, and AI are driving market expansion.
Positioning
Ekso Bionics is positioned as a key player in the medical exoskeleton market with its FDA-cleared EksoNR. In the industrial sector, EksoVest provides a competitive edge through its ergonomic design and worker safety benefits.
Total Addressable Market (TAM)
The global exoskeleton market is projected to reach billions of dollars in the coming years. Ekso Bionics is positioned to capture a significant portion through its medical and industrial solutions, focusing on early adoption in key markets.
Upturn SWOT Analysis
Strengths
- FDA-cleared medical exoskeleton (EksoNR)
- Established partnerships with rehabilitation centers
- Focus on improving worker safety and productivity with EksoVest
- Intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on regulatory approvals
- Relatively small market share in the overall robotics industry
- High product costs
Opportunities
- Expanding applications in military and consumer markets
- Partnerships with insurance providers for reimbursement of exoskeleton therapy
- Technological advancements in exoskeleton design and functionality
- Increasing awareness of the benefits of exoskeletons in various industries
Threats
- Competition from larger robotics companies
- Economic downturns affecting capital spending
- Changes in healthcare regulations
- Potential product liability issues
Competitors and Market Share
Key Competitors
- ReWalk Robotics (RWLK)
- Cyberdyne
- SuitX
- Ottobock
Competitive Landscape
Ekso Bionics has advantages in the medical market due to its FDA clearance. It faces competition from larger companies with broader product portfolios. Its industrial exoskeleton offerings compete on price and features.
Growth Trajectory and Initiatives
Historical Growth: Ekso Bionics has experienced revenue growth in recent years driven by increased adoption of its medical and industrial exoskeletons.
Future Projections: Analysts predict continued revenue growth for Ekso Bionics driven by increasing demand for its products and expansion into new markets.
Recent Initiatives: Recent strategic initiatives include partnerships with major industrial companies and expansion of the EksoNR platform into new rehabilitation centers.
Summary
Ekso Bionics is a specialized player in the exoskeleton market with FDA-cleared medical devices. The industrial side is more competitive, which may be cause for concern. Their growth depends on continuous technological innovation, partnerships, and overcoming reimbursement challenges for medical exoskeletons. Financial stability could be improved with more investment and market penetration. Success relies on maintaining a technological edge and effective market strategies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Ekso Bionics Investor Relations
- Company SEC Filings
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ekso Bionics Holdings Inc
Exchange NASDAQ | Headquaters San Rafael, CA, United States | ||
IPO Launch date 2014-01-16 | CEO & Director Mr. Scott G. Davis | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 61 | Website https://www.eksobionics.com |
Full time employees 61 | Website https://www.eksobionics.com | ||
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EVO, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. It also offers EksoCare offering an extended warranty and premium service options, repairs and maintenance services, and training programs. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.